Eli Lilly and Company (NYSE:LLY) Shares Up 1.3% – Still a Buy?

Shares of Eli Lilly and Company (NYSE:LLY) shot up 1.3% during mid-day trading on Tuesday. The stock traded as high as $1,177.06 and last traded at $1,157.6060. Approximately 2,121,006 shares were traded during mid-day trading, a decline of 29% from the average session volume of 2,977,780 shares. The stock had previously closed at $1,143.12.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Oncology expansion: The FDA granted orphan-drug designation to experimental cancer treatment olomorasib for pancreatic cancer, potentially providing development incentives and future market exclusivity. The FDA also expanded Jaypirca’s approval into the first-line CLL/SLL setting, broadening Lilly’s commercial cancer portfolio. Lilly oncology FDA developments
• Positive Sentiment: Obesity pipeline momentum: Data presented for Lilly’s oral GLP-1 candidate Foundayo showed greater weight loss and better blood-sugar control than oral semaglutide in adults with type 2 diabetes. Investors see a potential oral treatment as an important growth catalyst, while early work targeting the amylin pathway could support next-generation obesity-drug combinations. Foundayo clinical data
• Positive Sentiment: Pipeline and partnerships: Lilly completed early trials for a new basal-insulin candidate and advanced Phase 1 development of eltrekibart. It also expanded its Gate Bioscience drug-discovery collaboration, potentially worth more than $870 million, and joined a $120 million financing for healthcare company General Medicine. Gate Bioscience collaboration
• Positive Sentiment: Broader growth prospects: Analysts and financial commentators highlighted triple-digit growth in parts of Lilly’s oncology, immunology and neuroscience businesses, alongside continued leadership in metabolic health. Lilly’s TuneLab collaboration with insitro is also making machine-learning models available to selected biotech companies, potentially strengthening its innovation ecosystem. Lilly growth opportunity beyond weight loss
• Neutral Sentiment: Upcoming data: Lilly plans 21 dermatology presentations covering Ebglyss, Taltz and Zepbound-related research at the Fall Clinical Dermatology Conference. The updates could provide additional pipeline visibility but are not yet commercial results. Lilly dermatology data
• Negative Sentiment: Valuation concerns: LLY trades at a substantial premium to the broader market, meaning continued rapid growth is already reflected in the share price. Commentary also flagged potential pressure from falling U.S. prices for Mounjaro and Zepbound, leaving limited room for clinical, regulatory or commercial disappointments. Lilly valuation risk

Analyst Ratings Changes

A number of brokerages have issued reports on LLY. Jefferies Financial Group upped their price objective on Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a “buy” rating in a research report on Tuesday, June 9th. Leerink Partners increased their price objective on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an “outperform” rating in a research note on Thursday, June 25th. Wall Street Zen downgraded Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a report on Sunday, August 23rd. JPMorgan Chase & Co. upped their price target on Eli Lilly and Company from $1,400.00 to $1,500.00 and gave the stock an “overweight” rating in a research report on Monday, September 28th. Finally, Royal Bank Of Canada raised their price objective on Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 8th. One analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average price target of $1,311.96.

Eli Lilly and Company Stock Performance

The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. The firm has a market capitalization of $1.09 trillion, a PE ratio of 38.85, a price-to-earnings-growth ratio of 1.40 and a beta of 0.46. The firm’s 50 day moving average price is $1,175.28 and its 200-day moving average price is $1,090.99.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The company had revenue of $22.97 billion for the quarter, compared to the consensus estimate of $20.82 billion. During the same quarter in the prior year, the business posted $6.31 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, research analysts expect that Eli Lilly and Company will post 36.66 EPS for the current year.

Insider Buying and Selling

In other Eli Lilly and Company news, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the transaction, the executive vice president owned 54,147 shares of the company’s stock, valued at $63,628,139.70. This trade represents a 10.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the sale, the executive vice president directly owned 11,875 shares in the company, valued at $14,131,250. This represents a 29.63% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 13,500 shares of company stock worth $15,958,170. Company insiders own 0.14% of the company’s stock.

Institutional Investors Weigh In On Eli Lilly and Company

Institutional investors have recently modified their holdings of the company. Integrity Financial Corp WA lifted its holdings in Eli Lilly and Company by 1.3% in the second quarter. Integrity Financial Corp WA now owns 639 shares of the company’s stock valued at $767,000 after buying an additional 8 shares during the period. Willner & Heller LLC raised its holdings in shares of Eli Lilly and Company by 1.0% during the second quarter. Willner & Heller LLC now owns 917 shares of the company’s stock valued at $1,100,000 after purchasing an additional 9 shares during the period. Aspiring Ventures LLC raised its stake in Eli Lilly and Company by 3.7% during the 2nd quarter. Aspiring Ventures LLC now owns 255 shares of the company’s stock worth $306,000 after buying an additional 9 shares during the period. Wealthspan Partners LLC increased its holdings in shares of Eli Lilly and Company by 0.4% during the second quarter. Wealthspan Partners LLC now owns 2,120 shares of the company’s stock valued at $2,543,000 after acquiring an additional 9 shares in the last quarter. Finally, Navigoe LLC grew its position in Eli Lilly and Company by 8.7% in the 2nd quarter. Navigoe LLC now owns 113 shares of the company’s stock valued at $135,000 after purchasing an additional 9 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.